Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Phosphate Therapeutics acquires novel phosphate binder (PT20) from the Medical Research Council and secures development funding from Inventages Venture Capital for Compound’s Phase II Development

5 Mar 2012

Phosphate Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has signed an exclusive agreement with the Medical Research Council (MRC) to acquire the global rights to PT20, a novel Phase 2 ready phosphate binder for the treatment of hyperphosphataemia. The PT20 programme was initially supported by funding from the MRC’s Development Gap Fund and this deal was negotiated by MRC Technology on behalf of MRC. At the same time funding of up to €10.5m has been secured from Inventages Venture Capital (Inventages) to complete the Phase 2 development of PT20.

Patients with late-stage renal disease suffer from systemic phosphate accumulation, hyperphosphataemia, which enhances the risk of vascular calcification, leading to increased morbidity and mortality. Low phosphate diets and regular dialysis sessions are unable to prevent gradual phosphate accumulation, therefore, oral phosphate binders are required to reduce blood phosphate levels. Current treatments are often limited by at least one of the following problems: limited therapeutic dosing range, low specificity, high pill loading, gastrointestinal side effects, calcium loading or significant toxicity concerns.

PT20 is a novel phosphate binder with robust global IP protection that is based on adipate-doped iron oxide technology, allowing it to act as a ‘phosphate sponge’. Discovered and initially developed through clinical Phase 1 by MRC scientists based at the Human Nutrition Research Unit in Cambridge, UK; PT20 exhibits high specificity and efficacy in phosphate binding both in vitro and in vivo. In early studies PT20 appears to display characteristics that may position it as superior to current or known pipeline phosphate binders as it has the potential to overcome the key disadvantages in this class of therapeutics. Phosphate Therapeutics expects to initiate a confirmatory Phase I pharmacokinetic study in H2-2012 and initiate a Phase II dose-escalating, comparator study in 2013 for the treatment of hyperphosphataemia in patients with pre-dialysis and dialysis-dependent chronic kidney disease (CKD).

“We are pleased to have acquired PT20 from the Medical Research Council and secured funding from Inventages to further develop this high quality asset in addition to the Phase 3 development of ST10 for the treatment of iron deficiency anaemia in patients with CKD. It is evident that CKD patients also suffering with hyperphosphataemia are in need of a more effective therapy for this serious complication and we look forward to building upon the work already undertaken by the MRC on this programme to deliver a more effective therapy option.

Back to news